Beta Drugs Limited (NSE:BETA)
India · Delayed Price · Currency is INR 2,231.90
+28.50 (1.29%)
At close: Jul 31, 2026
Beta Drugs Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 4,102 | 3,848 | 3,624 | 2,957 | 2,271 | 1,838 |
Revenue Growth | 10.14% | 6.20% | 22.54% | 30.20% | 23.54% | 58.31% |
Gross Profit Gross Profit Growth | 2,342 | 2,136 | 1,500 | 1,143 | 974.47 | 714.89 |
Operating Income Operating Income Growth | 655.68 | 585.25 | 620.91 | 501.31 | 430.27 | 354.44 |
Net Income Net Income Growth | 455.86 | 414.83 | 424.19 | 364.37 | 307.19 | 248.28 |
Earnings Per Share EPS Growth | 44.31 | 40.92 | 42.02 | 37.90 | 30.43 | 24.59 |
EPS Growth | 6.77% | -2.62% | 10.87% | 24.55% | 23.74% | 111.72% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
India India Growth | 2,829 | 2,497 | 1,974 | 1,589 |
Export Export Growth | 794.85 | 460.34 | 296.96 | 249.04 |
Total Total Growth | 3,624 | 2,957 | 2,271 | 1,838 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 1,248 | 1,248 | 1,470 | 286.33 | 191.64 | 173.24 |
Total Debt Total Debt Growth | 1,478 | 1,478 | 1,381 | 147.11 | 203.32 | 206.03 |
Net Cash (Debt) Net Cash Growth | -229.59 | -229.59 | 89.68 | 139.22 | -11.68 | -32.79 |
Net Cash Growth | - | - | -35.58% | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -22.32 | -22.65 | 8.88 | 14.48 | -1.16 | -3.25 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | - | 372.86 | 361.44 | 309.3 | 233.83 | 296.28 |
Capital Expenditures CapEx Growth | - | -534.82 | -368.59 | -116.16 | -182.12 | -194.28 |
Free Cash Flow Free Cash Flow Growth | - | -161.95 | -7.14 | 193.15 | 51.71 | 102 |
Free Cash Flow Growth | - | - | - | 273.55% | -49.31% | -20.59% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 57.10% | 55.52% | 41.39% | 38.66% | 42.91% | 38.89% |
Operating Margin | 15.99% | 15.21% | 17.14% | 16.95% | 18.95% | 19.28% |
Pretax Margin | 14.82% | 14.13% | 15.72% | 16.49% | 18.08% | 18.66% |
Profit Margin | 11.11% | 10.78% | 11.71% | 12.32% | 13.53% | 13.51% |
FCF Margin | - | -4.21% | -0.20% | 6.53% | 2.28% | 5.55% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 50.37 | 28.94 | 45.35 | 32.55 | 19.62 | 21.90 |
P/FCF Ratio | - | - | - | 61.41 | 116.57 | 53.30 |
PS Ratio | 5.49 | 3.12 | 5.31 | 4.01 | 2.65 | 2.96 |